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Background: Children’s aversions to poor and mostly bitter tastes and their inability to swallow
tablets and capsules are major challenges in pediatric medicine. Sodium phenylbutyrate (NaPB)
is a lifesaving waste nitrogen, alternative to urea nitrogen, for individuals suffering from urea
cycle disorders. A major issue in the use of NaPB is its highly foul taste, which often leads to
children being unable to consume it, resulting in ineffective treatment, or alternatively, necessitating the application of the drug through a nasogastric tube or gastrostomy.
Methods: This study reviews the published data on a novel formulation of NaPB, Pheburane®
granules, which begin to release their NaPB after a lag time of ~10 seconds followed by a slow
release over several minutes.
Results: The taste-masked granule formulation of NaPB dramatically improves the acceptability of the drug by children and appears in initial studies to be both safe and effective.
Conclusion: While more studies are needed to substantiate and enrich these initial trials, the
available data provide a telling example where masking the drug taste of medicine for children
can sometimes be the difference between life and death.
Keywords: sodium phenylbutyrate, adherence, urea cycle disorders, Pheburane ®, taste,
children
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Children’s ability to consume drugs orally is often challenging due to their aversions
to bitter tastes and their inability to swallow tablets and capsules. In general, the foul
taste of drugs has been estimated to be a major hurdle to adherence for 91% of patients
with acute illness and 84% of patients with chronic illness.1
Finding solutions for this issue is critical for children in early years, before they
are able to swallow the whole tablet/capsule.
Palatability of medications is dictated to a large extent by taste; however, despite
the fact that a large percentage of active pharmaceutical ingredients (APIs) have foul
or unpleasant taste, this is not considered to be a major issue in the design of oral drugs
aimed at adults as they can typically be film coated or sugar coated, thereby masking
the taste of the API.2 Young children, not being able to swallow a tablet/capsule,
often need to receive liquids and (oro-)dispersible and chewable tablets, making taste
masking a major challenge.
In a recent pragmatic study among hospitalized children, nearly one-third of the
participants reported medicine refusal, which correlated significantly with child’s age,
drug taste, texture, and volume or quantity of the medicine.3

2141

submit your manuscript | www.dovepress.com

Patient Preference and Adherence 2016:10 2141–2144

Dovepress

© 2016 Koren et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/PPA.S117506

Dovepress

Koren et al

Sodium phenylbutyrate (NaPB) is an effective waste
nitrogen and an alternative to urea nitrogen for individuals
suffering from urea cycle disorders (UCD). 4–6 Without
such therapy, these patents develop liver damage and may
succumb to hepatic encephalopathy at a young age.5 A major
issue in the therapeutic use of NaPB is its extremely foul taste,
often leading children not to be able to consume it, resulting in ineffective treatment, or alternatively, necessitating
delivery of the drug through a nasogastric tube (NGT) or
gastrostomy. The development of a tasteless taste-masked
granule formulation of NaPB that can be swallowed before
taste receptors are stimulated is an example of a therapeutic
victory achieved through technological solutions.

The urea cycle and nitrogen scavengers
Normally, nitrogen produced by protein breakdown is
removed by the liver and, to a lesser extent, by the kidney,
through a cycle of five biochemical reactions collectively
called the urea cycle (UC) (or ornithine cycle). Inherited
inborn deficiencies of UC enzymes, or certain cases of chronic
liver failure, can lead to accumulation of ammonia and result
in hepatic encephalopathy. Deficiencies of N-acetylglutamate
synthase, carbamoyl phosphate synthetase, ornithine transcarbamylase, argininosuccinic acid synthetase, argininosuccinic acid lipase, and arginase are all very rare conditions.
The lack of effective early treatment results in accumulation
of ammonia and irreversible brain damage.6
The basis of therapy for this condition, in addition to
a very restricted protein diet to decrease nitrogen burden,
is through the use of nitrogen scavengers that utilize
alternative scavenging pathways, such that hippurate and
phenylacetyl-glutamine, the metabolites of benzoate and
NaPB, take the role naturally played by urea to excrete waste
nitrogen.5–8 NaPB is a prodrug, which is rapidly metabolized
to phenylacetate. Phenylacetate is a metabolically active
compound that conjugates with glutamine via acetylation
to form phenylacetylglutamine, which is then excreted by
the kidneys. On a molar basis, phenylacetylglutamine is
comparable to urea (each containing 2 mol of nitrogen) and
therefore provides an alternate vehicle for the excretion of
waste nitrogen. Based on studies of phenylacetylglutamine
excretion in patients with UCD, it is estimated that, for each
gram of NaPB administered, between 0.12 g and 0.15 g of
phenylacetylglutamine nitrogen are produced, thus addressing the elevated plasma ammonia and glutamine levels.7,8
Because the needed doses are proportional to protein intake,
this translates into large amounts of foul taste drug to be
optimally taken during meals.
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NaPB was introduced experimentally in 1987 and was
approved for UCD by the US Food and Drug Administration
in 1996 and by the European Medicines Agency in Europe
in 1999.8 The major issue with the clinical use of this very
effective scavenger has been its notoriously foul taste.8 As
young children with inborn errors in the UC are a significant
group of patients for this therapy, the offensive odor is a
major cause for poor adherence and, therefore, can lead to
irreversible brain damage secondary to hyperammonemia.
Due to this serious challenge in drug administration, children
are often given NaPB through NGT or gastrostomy.9
As many APIs are poorly palatable, there are common
practical attempts used by parents and medical staff to either
dilute the drug, and hence its foul taste, or try to obscure
the taste by mixing or sprinkling it with foods or drinks.2
These approaches may lead to impaired efficacy due to
incomplete drug dosing, if the mixture is not fully consumed,
and may also cause the child to develop aversion to the foods
used in the masking process. The use of milk for this purpose
in young children, who consume mostly milk, is a classical
example of this challenge.
The sciences involved in taste masking are rapidly
evolving to present clinical solutions for important medications, especially for young children who cannot yet swallow
whole tablets or capsules. An excellent recent review by the
European Formulation Initiative is highly worth reading.2
It appears that .25 different bitter taste receptors have been
identified to date. Bitter receptor antagonists can bind to bitter
receptor sites and hence render the drug tasteless. However,
presently no bitter receptor antagonists are already in clinical
pediatric use, except for sodium chloride.

Methods
The published literature was reviewed through Medline
and EMBASE for publications on NaPB and the tastemasked granule formulation of NaPB. Relevant articles
were reviewed and evaluated as to the efficacy and safety in
individuals treated for UCD.

Results and discussion
The taste-masked granule formulation of
NaPB initial experience
To overcome the serious issue of foul bitter taste of NaPB,
a French manufacturer developed a taste-masked granule
formulation of the chemical. Over the years, attempts to
mask this bitter and extremely unpleasant taste in food and
drink have failed, causing these children to be undertreated,
with the resultant poor metabolic control. The taste-masked
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granule formulation of NaPB begins to release their NaPB
after a lag time of ~10 seconds followed by a slow release
over several minutes. In contrast, the market-licensed NaPB
releases the active drug fully and immediately, leading to
immediate release of the foul taste. Hence, the taste-masked
granule formulation of NaPB creates a window of opportunity
to completely swallow the formulation before its taste and
odor become apparent.10
In the taste-masked granule formulation of NaPB granules
in 13 adult volunteers, 5 g of granules were bioequivalent
to the licensed product, while showing significantly higher
acceptance, less bitterness, and less saltiness (P,0.01).11,12
These results led the investigators to initiate the first
French nationwide 1-year cohort study on 25 patients, of
whom 21 were children.13 All of them suffered from UCD,
and prior to introducing the taste-masked granule formulation
of NaPB, all were maintained on another nitrous scavenger,
either NaPB or sodium benzoate. Five patients eventually
did not participate in the trial and 20 patients had analyzable
results. The majority (n=15) of them suffered from ornithine
transcarbamylase deficiency, and five patients suffered
from arginosuccinate synthase type 1 deficiency. Clinically,
11 patients exhibited developmental delay, seven patients had
epilepsy or neurological impairment, and six patients suffered
from liver impairment. Importantly, 10 patients had hyperammonemic episodes in the 6 months prior to trying the granules (ranging between 1 and 3 episodes). The taste-masked
granule formulation of NaPB was given orally in a total dose
ranging from 1.5 g/d to 15 g/d (mean [standard deviation],
5.2 [3.3], or 211 [112] mg/kg/d). Overall, the cohort was
treated for a period between 1 month and 11 months.
Most patients joined the study due to major issues with the
taste of the marketed NaPB. The results of comparing taste
and overall acceptability mirrored those shown in the healthy
volunteers, with significantly less bitterness and dramatically
improved visual analog scale scores of acceptance with the
taste-masked granule formulation of NaPB. Prior to receiving
the granules, some patients received the marketed product by
NGT, one patient received through gastrostomy, and the rest
were marked as “impossible to take the marketed product”,
“difficult”, “need for reformulation”, and “need to be treated
with benzoate”. With the taste-masked granule formulation
of NaPB, all 20 treated patients were marked as “normal
per os”. The study did not follow formal measurements of
adherence beyond these descriptors, and such data will be
important to generate in future studies, both for short-term
use and long-term use. Probably, the most important clinical
outcome was the change in the episodes of hyperammonemia,
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with 10 patients experiencing between 1 and 3 episodes over
6 months prior to the taste-masked granule formulation of
NaPB and none of them experiencing it in the 3–11 months
after starting the taste-masked granule formulation of NaPB.
With the lack of formal measurements of adherence, this
dramatic clinical effect can serve as a surrogate of patients
taking their medication regularly.
In January 2016, the authors reported the results of further
follow-up of part of the original cohort.14 Patients were followed up every 6–12 months at one reference center. Unlike
the original cohort, the follow-up was not compulsory and
participants had to have at least 6 more months of treatment
over the original cohort described earlier.
From the original cohort of 25 patients, this review
includes seven patients who continued and used granules, for
over 1 year in one center, and one new patient from the same
center who was exposed to the taste-masked granule formulation of NaPB for 8 months. Eight patients suffered from
ornithine transcarbamylase deficiency (3), arginosuccinate
synthase deficiency (3), carbamoyl phosphate synthase type
1 deficiency (1), and hyperornithinemia–hyperammonemia–
homocitrullinuria (1). The granules given in a range of
2–9 g/d (mean [standard deviation], 5.6 [2.7]). The mean
duration of exposure was 1.85 (0.5) years.
While there were five children requiring cognitive and
social-educational support, neurological examination was
either improved or stayed stable. There was a slow but steady
growth in weight, height, and body surface area in the six
children with available data.
In terms of number of hyperammonemic episodes,
there were no such episodes among the eight followed
up patients during the extended 8–30 months of the tastemasked granule formulation of NaPB. In a similar manner,
the median (interquartile range) values of maximal plasma
ammonia continued to decrease from 115 (75–185 µM) to
45 (30–76 µM) (P=0.039) and levels of glutamine stayed
unchanged. However, while the authors state that “in a representative subset of this cohort, the protective effect of the
taste-masked granules against metabolic decompensations
was sustained”, it is impossible to know whether a similar
effect was achieved in the rest of the patients who were not
followed up. In other words, it is not necessarily clear that this
subcohort was representative of the whole initial cohort.

Conclusion
While more studies are needed to substantiate and enrich
these initial trials, this experience provides a telling example
where masking the drug taste in children can sometimes
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be the difference between life and death. This approach can
be adopted to other important pediatric drugs with foul taste
(eg, cefuroxime).

Abbreviations
APIs, active pharmaceutical ingredients; NaPB, sodium
phenylbutyrate; NGT, nasogastric tube; UCD, urea cycle
disorders.
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